China Pharma Holdings Inc (CPHI) - Total Assets
Based on the latest financial reports, China Pharma Holdings Inc (CPHI) holds total assets worth $15.98 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CPHI operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
China Pharma Holdings Inc - Total Assets Trend (2001–2024)
This chart illustrates how China Pharma Holdings Inc's total assets have evolved over time, based on quarterly financial data. See China Pharma Holdings Inc net assets for net asset value and shareholders' equity analysis.
China Pharma Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
China Pharma Holdings Inc's total assets of $15.98 Million consist of 22.0% current assets and 78.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.2% |
| Accounts Receivable | $281.07K | 1.9% |
| Inventory | $2.27 Million | 15.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.09 Million | 47.6% |
| Goodwill | $-391.84K | -2.6% |
Asset Composition Trend (2001–2024)
This chart illustrates how China Pharma Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CPHI company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Pharma Holdings Inc's current assets represent 22.0% of total assets in 2024, an increase from 0.9% in 2001.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2024, up from 0.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 47.6% of total assets.
China Pharma Holdings Inc Competitors by Total Assets
Key competitors of China Pharma Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
|
China | CN¥5.91 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥12.01 Billion |
China Pharma Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.35 | 0.79 | 0.47 |
| Quick Ratio | 0.10 | 0.26 | 0.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.29 Million | $-1.02 Million | $-6.08 Million |
China Pharma Holdings Inc - Advanced Valuation Insights
This section examines the relationship between China Pharma Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.37 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | $14.89 Million |
| Market Capitalization | $2.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values China Pharma Holdings Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: China Pharma Holdings Inc's assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for China Pharma Holdings Inc (2001–2024)
The table below shows the annual total assets of China Pharma Holdings Inc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.89 Million | -9.60% |
| 2023-12-31 | $16.47 Million | -7.39% |
| 2022-12-31 | $17.78 Million | -21.48% |
| 2021-12-31 | $22.65 Million | +7.25% |
| 2020-12-31 | $21.12 Million | -5.02% |
| 2019-12-31 | $22.24 Million | -51.00% |
| 2018-12-31 | $45.38 Million | -24.31% |
| 2017-12-31 | $59.95 Million | -23.65% |
| 2016-12-31 | $78.52 Million | -19.24% |
| 2015-12-31 | $97.22 Million | -26.39% |
| 2014-12-31 | $132.08 Million | -16.20% |
| 2013-12-31 | $157.61 Million | -3.45% |
| 2012-12-31 | $163.24 Million | +4.38% |
| 2011-12-31 | $156.39 Million | +18.70% |
| 2010-12-31 | $131.75 Million | +30.52% |
| 2009-12-31 | $100.94 Million | +33.75% |
| 2008-12-31 | $75.47 Million | +72.68% |
| 2007-12-31 | $43.71 Million | +53.28% |
| 2006-12-31 | $28.51 Million | +33945591.67% |
| 2005-12-31 | $84.00 | 0.00% |
| 2004-12-31 | $84.00 | -99.97% |
| 2003-12-31 | $298.63K | -29.85% |
| 2002-12-31 | $425.67K | 0.00% |
| 2001-12-31 | $425.67K | -- |
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more